cis-Platinum as adjunctive to surgery in early stage ovarian carcinoma: effects on lymphoid cell subpopulations.
The effect of single-drug cis-diamminedichloroplatinum (CDDP) treatment on the distribution of T-lymphocyte subsets and monocytes was determined using monoclonal antibodies and a flow cytometry technique. Thirty-nine patients with radically operated ovarian carcinoma received postoperative treatment with six cycles of CDDP 50 mg/m2, and were examined either before, during, or after chemotherapy. During treatment, the number of OKT4+ (mainly T-helper) cells was reduced, whereas the number of OKT8+ (mainly T-suppressor/cytotoxic) cells was increased. Four to six months after the CDDP treatment was ended, these aberrations were no longer seen. The number of 1D5+ cells (monocytes) was not influenced by the treatment. It is concluded that no long-lasting change in the distribution of immunocompetent cells could be detected after this regimen of CDDP treatment.
D000328:Adult; D000368:Aged; D002277:Carcinoma / Q000188:drug therapy* / Q000276:immunology / Q000601:surgery; D002945:Cisplatin / Q000494:pharmacology* / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007958:Leukocyte Count; D008214:Lymphocytes / Q000145:classification / Q000187:drug effects*; D008875:Middle Aged; D009000:Monocytes / Q000187:drug effects; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000601:surgery
D002945:Cisplatin